Abcellera Biologics Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | 108.3 | 45.7 | 26.1 | 26.5 | 29.3 | 14.9 | 15.2 | 12.6 | 19.2 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | 55.2 | 25.3 | 13.4 | 12.6 | 12.0 | 6.2 | 6.0 | 5.2 | 6.3 | 11.9 | 12.9 | 26.4 | 43.6 | 36.8 | 26.7 | 23.3 | 29.6 | 28.3 | 30.9 | 42.3 | 13.5 | 13.4 | 36.5 | |
| – | – | – | – | – | – | – | 15.5 | 11.4 | 6.2 | 5.9 | 4.4 | 2.5 | 2.5 | 2.5 | 2.5 | 1.8 | 1.6 | 1.1 | 1.4 | 1.2 | 0.8 | 0.7 | 0.8 | 0.6 | 1.0 | 1.6 | 1.1 | 1.1 | 2.7 | |
| – | – | – | – | – | – | – | 52.7 | 23.7 | 11.6 | 11.4 | 10.7 | 5.1 | 4.5 | 4.6 | 5.5 | 10.9 | 11.7 | 23.1 | 40.3 | 33.5 | 22.4 | 19.6 | 24.4 | 21.6 | 28.2 | 40.1 | 11.9 | 12.5 | 34.7 | |
| – | – | – | – | – | – | – | 72.7 | 30.5 | 15.8 | 16.4 | 16.7 | 8.1 | 7.3 | 7.4 | 9.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | 1,566.6 | 90.4 | 26.9 | 25.9 | 23.7 | 18.0 | 10.7 | 19.5 | 14.8 | 35.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | 0.1% | 1.1% | 3.7% | 3.9% | 4.2% | 5.6% | 9.4% | 5.1% | 6.7% | 2.8% | -10.0% | -5.1% | -7.3% | -9.7% | -19.2% | -25.7% | -21.8% | -21.8% | -13.7% | -10.2% | -17.1% | -17.8% | -7.4% | |
| Margins | ||||||||||||||||||||||||||||||
| – | – | – | 12.9% | 41.2% | 73.0% | 88.4% | 100.0% | 95.4% | 94.7% | 94.7% | 87.9% | 85.7% | 85.9% | 85.6% | 86.3% | 88.0% | 88.6% | 96.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 89.5% | 79.1% | 75.0% | |
| – | – | – | -35.5% | -40.1% | -25.1% | -23.6% | 66.9% | 73.3% | 69.3% | 63.9% | 54.5% | 55.5% | 53.2% | 55.7% | 44.6% | -40.5% | -80.1% | -414.6% | -623.8% | -634.9% | -814.7% | -934.6% | -1,091.6% | -1,395.3% | -847.6% | -739.7% | -289.0% | -267.6% | -340.3% | |
| – | – | – | -19.0% | -29.0% | 13.3% | 1.0% | 51.0% | 55.2% | 51.2% | 47.4% | 40.9% | 41.9% | 39.5% | 41.2% | 32.7% | -27.7% | -50.9% | -256.3% | -385.0% | -410.5% | -463.8% | -533.3% | -564.8% | -726.2% | -503.9% | -486.0% | -194.9% | -181.7% | -248.8% | |
| – | – | – | -11.2% | -54.3% | 66.3% | 28.5% | 3.5% | 27.9% | 49.7% | 48.6% | 50.5% | 34.7% | 56.3% | 26.6% | 42.3% | 33.5% | -129.0% | -135.8% | -318.4% | -357.3% | -513.0% | -596.8% | -646.2% | -617.2% | -423.3% | -433.4% | -231.7% | -238.9% | -271.2% | |
| Returns | ||||||||||||||||||||||||||||||
| – | – | – | -21.6% | -39.0% | 3.3% | 0.3% | 14.3% | 24.9% | 23.7% | 22.1% | 15.0% | 17.0% | 16.5% | 19.9% | 12.9% | -4.2% | -6.2% | -10.9% | -12.7% | -13.0% | -13.8% | -16.3% | -15.4% | -16.4% | -16.5% | -17.8% | -15.1% | -15.3% | -18.4% | |
| – | – | – | -9.4% | – | 1.9% | 0.2% | 11.8% | 21.1% | 19.9% | 18.0% | 11.6% | 12.9% | 12.6% | 16.0% | 10.3% | -3.3% | -4.8% | -8.5% | -9.8% | -10.0% | -10.9% | -12.6% | -12.0% | -12.5% | -11.8% | -12.7% | -10.8% | -11.0% | -12.6% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||
| – | – | – | -3.3 | – | -112 | -88 | -591 | -684 | -790 | -515 | -472 | -542 | -787 | -367 | -381 | -187 | -174 | -167 | -127 | -118 | -143 | -122 | -152 | -155 | -88 | -78 | -123 | -71 | -114 | |
| – | – | – | – | – | -18.0 | -12.5 | -3.5 | -2.0 | -2.4 | -1.7 | -2.0 | -1.7 | -2.5 | -1.0 | -1.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | 43.6% | – | 58.6% | 62.7% | 82.6% | 84.8% | 84.0% | 81.3% | 77.8% | 75.8% | 76.1% | 80.5% | 80.0% | 80.7% | 77.7% | 78.2% | 77.4% | 77.2% | 78.7% | 77.4% | 77.6% | 76.1% | 71.8% | 71.1% | 71.3% | 71.8% | 68.5% | |
| – | – | – | 0.4 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Per Share | ||||||||||||||||||||||||||||||
| – | – | – | -0.01 | -0.02 | 0.01 | 0.00 | 0.37 | 0.74 | 0.84 | 0.75 | 0.49 | 0.66 | 0.70 | 0.79 | 0.53 | -0.17 | -0.26 | -0.45 | -0.50 | -0.50 | -0.52 | -0.60 | -0.55 | -0.56 | -0.55 | -0.57 | -0.49 | -0.47 | -0.54 | |
| – | – | – | 0.05 | 0.06 | 0.09 | 0.11 | 0.73 | 1.35 | 1.64 | 1.59 | 1.19 | 1.57 | 1.78 | 1.91 | 1.61 | 0.63 | 0.50 | 0.17 | 0.13 | 0.12 | 0.11 | 0.11 | 0.10 | 0.08 | 0.11 | 0.12 | 0.25 | 0.26 | 0.22 | |
| 0.08 | – | – | 0.04 | 0.04 | 0.38 | 0.34 | 2.59 | 2.99 | 3.56 | 3.42 | 3.26 | 3.88 | 4.26 | 3.96 | 4.09 | 4.20 | 4.14 | 4.09 | 3.96 | 3.86 | 3.78 | 3.66 | 3.58 | 3.44 | 3.37 | 3.23 | 3.24 | 3.10 | 2.93 | |
| – | – | – | -0.01 | -0.03 | 0.06 | 0.03 | 0.03 | 0.38 | 0.82 | 0.77 | 0.60 | 0.54 | 1.00 | 0.51 | 0.68 | 0.21 | -0.65 | -0.24 | -0.42 | -0.44 | -0.58 | -0.67 | -0.63 | -0.48 | -0.47 | -0.51 | -0.58 | -0.62 | -0.59 | |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.